Clinically approved liposomes, polymers, and albumin drugs
| Name | Main NP ingredient (s) | Active pharmaceutical ingredient (s) | Approval (year) | Indication |
|---|---|---|---|---|
| Liposome-based NPs | ||||
| Doxil/Caelyx | Liposome; PEG | Doxorubicin | FDA (1995) EMA (1996) | Ovarian cancer; Kaposi’s sarcoma; osteomedullary melanoma |
| DaunoXome | Liposome | Daunorubicin | FDA (1996) | Kaposi’s sarcoma |
| AmBisone | Liposome | Amphotericin B | FDA (1997) | Systemic fungal infection |
| DepoCyt/DepoCyte | Liposome | Cytarabine | FDA (1999) EMA (2001) | Meningitis due to lymphoma |
| Myocet | Liposome | Doxorubicin | EMA (2000) | Breast cancer |
| Visudyne | Liposome | Vitipofen | FDA (2000) EMA (2000) | Wet senile macular degeneration |
| DepoDur | Liposome | Morphine sulfate | FDA (2004) | Postoperative pain |
| Mepact | Liposome | Mifenin | EMA (2009) | Osteosarcoma |
| Exparel | Liposome | Bupivacaine | FDA (2011) EMA (2020) | Postoperative pain |
| Marqibo | Liposome | Vincristine | FDA (2012) | Leukemia |
| Onivyde | Liposome; PEG | Irinotecan | FDA (2015) EMA (2016) | Pancreatic cancer |
| Vyxeos | Liposome | Daunorubicin/cytarabine | FDA (2017) EMA (2018) | Leukemia |
| Shingrix | Liposome | Recombinant herpes zoster vaccine | EMA (2018) | Herpes zoster; postherpetic neuralgia |
| Arikayce | Liposome | Amikacin sulfate | FDA (2018) EMA (2020) | Lung disease |
| Lipusu | Liposome | Paclitaxel | China (2006) | Breast, lung, and ovarian cancer |
| Polymer-based NPs | ||||
| Lupron Depot | PLGA | Leuprorelin acetate | FDA (1989) | Advanced prostate cancer |
| Adagan | PEG | ADA | FDA (1990) | ADA-SCID |
| SMANCS | Styrene maleic acid polymer | New oncomycin | Japan (1993) | Liver cancer; renal carcinoma |
| Oncaspar | PEG | ASNase | FDA (1994) | Acute lymphoblastic leukemia |
| Sandostatin Lar | PLGA | Octreotide acetate | FDA (1998) | Acromegaly |
| Trelstar | PLGA | Triptorelin | FDA (2000) | Acute lymphoblastic leukemia |
| Peglntron | PEG | Interferon α 2b | FDA (2001) | Hepatitis C |
| Pegasys | PEG | Interferon α 2a | FDA (2002) | Hepatitis B; hepatitis C |
| Neulasta | PEG | G-CSF | FDA (2002) EMA (2002) | Chemotherapy induced neutropenia |
| Somavert | PEG | HGH receptor antagonist | FDA (2003) | Acromegaly |
| Macugen | PEG | Anti-VEGF nucleic acid ligand | FDA (2004) | Neovascular age-related macular degeneration |
| Mircera | PEG | Erythropoietin β | FDA (2007) | Anemia associated with chronic kidney disease |
| Genexol-PM | mPEG-PLA | Paclitaxel | South Korea (2007) | Chemotherapy induced neutropenia |
| Cimzia | PEG | Anti-TNF Fab′ | FDA (2008) | Crohn’s disease; rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis |
| Krystexxa | PEG | Uric acid | FDA (2010) | Chronic ventilation |
| Bydureon | PLGA | Exenatide synthetic | FDA (2012) | Type II diabetes |
| Andostatin Lar | PLGA | Paretotide | FDA (2014) | Acromegaly |
| Plegridy | PEG | Interferon β 1a | FDA (2014) | Recurrent multiple sclerosis |
| Movantik | PEG | Naloxone | FDA (2014) | Opioid induced constipation |
| Adynovate | PEG | Factor VIII | FDA (2015) | Hemophilia A |
| Triptodur Kit | PLGA | Triptorelin | FDA (2017) | Central precocious puberty |
| Sublocade | PLGA | Buprenorphine | FDA (2017) | Moderate to severe opiate use disorder |
| Palynziq | PEG | Phenylalanine ammonia lyase | FDA (2018) | Phenylketonuria |
| Jivi | PEG | Factor VIII | FDA (2018) | Hemophilia A |
| Eligard | PLGA | Leuprolide acetate | FDA (2002) | Prostate cancer |
| Zinostatin Stimalamer | SMA | NCS | Japan (1994) | Primary unresectable hepatocellular carcinoma |
| Albumin-based NPs | ||||
| Abraxane | Albumin | Paclitaxel | FDA (2005) EMA (2008) | Lung cancer; metastatic breast cancer; metastatic pancreatic cancer |
| Tanzeum | Albumin | GLP-1/HSA | FDA (2014) | Diabetes |
| Idelvion | Albumin | rIX-FP | FDA (2016) | Hemophilia B |